Tinnitus-Pipeline Review, H1 2015

Tinnitus-Pipeline Review, H1 2015

  • Products Id :- GMDHC6288IDB
  • |
  • Pages: 64
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Tinnitus-Pipeline Review, H1 2015


Global Markets Direct's, 'Tinnitus-Pipeline Review, H1 2015', provides an overview of the Tinnitus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tinnitus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Tinnitus

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Tinnitus and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Tinnitus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Tinnitus pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Tinnitus

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Tinnitus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Tinnitus Overview 7

Therapeutics Development 8

Pipeline Products for Tinnitus-Overview 8

Pipeline Products for Tinnitus-Comparative Analysis 9

Tinnitus-Therapeutics under Development by Companies 10

Tinnitus-Therapeutics under Investigation by Universities/Institutes 11

Tinnitus-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Tinnitus-Products under Development by Companies 15

Tinnitus-Products under Investigation by Universities/Institutes 16

Tinnitus-Companies Involved in Therapeutics Development 17

AudioCure Pharma GmbH 17

Auris Medical Holding AG 18

Flexion Therapeutics, Inc. 19

Knopp Biosciences LLC 20

Merz Pharma GmbH & Co. KgaA 21

Otonomy, Inc. 22

Sound Pharmaceuticals, Inc. 23

Synphora AB 24

Tinnitus-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 33

acamprosate-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

AM-102-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

AUT-00063-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

AUT-3-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Drug to Activate KCNQ for Tinnitus-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

esketamine hydrochloride-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

gacyclidine SR-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

latanoprost-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

neramexane mesylate-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Small Molecules for Tinnitus-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

SPI-1005-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

SPI-3005-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Tinnitus-Recent Pipeline Updates 50

Tinnitus-Dormant Projects 54

Tinnitus-Product Development Milestones 55

Featured News & Press Releases 55

Jan 14, 2015: Auris Medical Holding AG Achieves 50% Enrolment Milestone in Post-Acute Tinnitus Stratum of TACTT3 Clinical Trial 55

Jun 04, 2014: Autifony Therapeutics awarded 2.2 million to progress first-in-classdrug for tinnitus into Phase IIa study 55

Mar 31, 2014: Published Analysis Confirms Positive Results from Auris Medical's Phase IIb Study with AM-101 in Treatment of Acute Inner Ear Tinnitus 56

Sep 09, 2013: Second Phase II Clinical Trial Confirms Safety and Efficacy Trends for Auris Medical AG's AM-101 in Treatment of Acute Peripheral Tinnitus 57

Jun 04, 2013: Autifony Therapeutics Initiates Phase I Trial Of AUT-00063 For Treatment Of Hearing Loss And Tinnitus 58

May 17, 2013: Auris Medical Announces Presentation Of Safety Results From AM-101 Clinical Development At 7th International TRI Tinnitus Conference 59

Apr 30, 2013: Auris Medical Selects Medidata Clinical Cloud To Support New Tinnitus Research 60

Feb 12, 2013: Auris Medical Completes Enrollment In Phase II Study Of AM-101 For Treatment Of Acute Peripheral Tinnitus 60

Aug 10, 2012: Auris Medical Completes Enrolment In First Stage Of AM-101 TACTT1 Study 61

Jun 26, 2012: Auris Medical Presents Key Results From Phase IIb Study Of AM-101 At International TRI Tinnitus Conference 61

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

Number of Products under Development for Tinnitus, H1 2015 8

Number of Products under Development for Tinnitus-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Tinnitus-Pipeline by AudioCure Pharma GmbH, H1 2015 17

Tinnitus-Pipeline by Auris Medical Holding AG, H1 2015 18

Tinnitus-Pipeline by Flexion Therapeutics, Inc., H1 2015 19

Tinnitus-Pipeline by Knopp Biosciences LLC, H1 2015 20

Tinnitus-Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 21

Tinnitus-Pipeline by Otonomy, Inc., H1 2015 22

Tinnitus-Pipeline by Sound Pharmaceuticals, Inc., H1 2015 23

Tinnitus-Pipeline by Synphora AB, H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 27

Number of Products by Stage and Mechanism of Action, H1 2015 29

Number of Products by Stage and Route of Administration, H1 2015 31

Number of Products by Stage and Molecule Type, H1 2015 32

Tinnitus Therapeutics-Recent Pipeline Updates, H1 2015 50

Tinnitus-Dormant Projects, H1 2015 54

List of Figures

Number of Products under Development for Tinnitus, H1 2015 8

Number of Products under Development for Tinnitus-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 26

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Top 10 Routes of Administration, H1 2015 30

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

AudioCure Pharma GmbH

Auris Medical Holding AG

Flexion Therapeutics, Inc.

Knopp Biosciences LLC

Merz Pharma GmbH & Co. KgaA

Otonomy, Inc.

Sound Pharmaceuticals, Inc.

Synphora AB

Tinnitus Therapeutic Products under Development, Key Players in Tinnitus Therapeutics, Tinnitus Pipeline Overview, Tinnitus Pipeline, Tinnitus Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com